Mitral regurgitation has high morbidity and mortality. The application of transcatheter edge-to-edge mitral valve repair (TEER) has provided more options for the management of primary and secondary mitral regurgitation. With the accumulation of operator experience, the improvement of equipment, and the optimization of intraoperative imaging, TEER can be applied to more complex or critically ill patients. The incidence of TEER-related adverse events is low, but some complications that may occur are potentially dangerous. TEER-related complications and their treatment methods are the guarantee of safe and effective operation. This article discusses the main possible complications of TEER and the corresponding management strategies.
This article presented the clinical diagnosis and management of a patient with severe aortic regurgitation and moderate aortic stenosis who underwent transcatheter aortic valve replacement complicated with coronary obstruction and retroperitoneal hematoma. The hemodynamics collapsed during the procedure, and transcatheter aortic valve replacement was performed under support of extracorporeal membrane oxygenation and coronary protection. After a negative coronary angiography, the wire was extracted, but a repeated angiography showed left coronary obstruction, so a coronary stent was implanted to the ostium of left coronary artery through the grid of the valve stent. Abdominal CT showed a giant retroperitoneal hematoma 2 weeks after transcatheter aortic valve replacement, and the emergent angiography indicated contrast leakage from left external iliac artery, so a balloon compression was performed followed by a covered stent implantation. This article also provided the clinical characteristics, risk factors and management of coronary obstruction and vascular complication for clinical reference.
Patients with bicuspid aortic valve (BAV) are characterized by asymmetric anatomy, severe calcification and combined aortic dilatation. Compared with tricuspid aortic valve stenosis patients, patients with BAV stenosis confront with greater surgical risks in transcatheter aortic valve replacement (TAVR), including paravalvular leak, aortic valve rupture, coronary artery obstruction, atrioventricular block and so on. However, with the advent of new generation of prosthetic valves and optimization of surgical strategies, several studies have shown that TAVR is safe and effective in the treatment of BAV stenosis. Therefore, we aim to provide an overview of the use of TAVR in patients with BAV stenosis.